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Eye Health Council of Ontario (EHCO)
It has long been clear to those involved in eye health care in On-
tario that there is a need for a venue to promote inter-professional 
collaboration to optimize the provision of eye care and dissemi-
nate these concepts to appropriate stakeholders.   Approximately 
six years ago, an informal Eye Care Council was created by the 
Ontario Association of Optometrists and Ontario Medical Associa-
tion Section on Ophthalmology for this purpose.  This has since 
evolved into the Eye Health Council of Ontario (EHCO).
The inaugural meeting of EHCO took place on December 3, 2010, 
following the March 31, 2010 recommendations of the Health Profes-
sions Regulatory Advisory Council (HPRAC) “Report to the Minister 
of Health and Long-Term Care on Inter-professional Collaboration 
Among Eye Care Health Professionals”. This report envisioned a 
Council composed of optometrists and ophthalmologists working 
together, similar to the innovative model in Nova Scotia, building 
upon the foundation already established in Ontario.
The mandate of EHCO is to support the provision of acces-
sible, quality eye care to the population of Ontario by ensuring 
the most effective use of the continuum of eye care professionals 
in the interests of patient safety, quality of care, and cost-effective 
delivery.
EHCO will also provide a unified voice for eye care issues at the 
Ministry of Health and Long-Term Care (MOHLTC), and serve as a 
mechanism to develop common collaborative guidelines for patient 
care, and as an ideal atmosphere for inter-professional collaboration 
outside the regulatory framework.  Membership includes fourteen 
individuals from both ophthalmology and optometry representing 
academic, political and regulatory bodies of each profession.  Both 
professions agreed to a governance structure wherein two co-chairs 
shall oversee the meetings; one chair shall be an optometrist, the 
other an ophthalmologist. Items require a 2/3 majority vote to be 
approved by EHCO. The council shall meet four times annually and 
host an extended meeting once per year, inviting all appropriate 
stakeholders (i.e. opticians, industry, CNIB, family physicians, etc). 
There are two observers from each College (College of Physicians and 
Surgeons of Ontario (CPSO) and College of Optometrists of Ontario 
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Background
Diabetes is a disease that is grow-
ing rapidly in both incidence and 
prevalence in Ontario (dramatically 
exceeding the global estimates of  
the World Health Organization), 
and poses a major public health 
challenge on many fronts. 1 More 
specifically, diabetic retinopathy is 
the most common cause of  new 
cases of  legal blindness in people 
of  working age. 2,12 Approximately 
12% of  new cases of  blindness are 
caused by diabetic retinopathy, and 
people with diabetic retinopathy 
are 25 to 29 times more likely than 
the general population to become 
blind within four years. 3,13 As 
many as 20% of  patients newly 
diagnosed with Type 2 Diabetes 
(90% of cases of diabetes are Type 2), 
have some evidence of  diabetes-
related eye disease at the time of  
diagnosis, and approximately 5% 
will need immediate treatment to 
help prevent vision loss. Within 
seven years of  diagnosis, 50% of  
patients with Type 2 Diabetes  
will develop diabetes-related 
changes to the eye. By 15 years, 
this number increases to as many 
as 85%, with 25% requiring 
treatment.3 Essentially 100% of  
patients with Type 1 Diabetes will 
exhibit some diabetes-related eye 
disease 15 to 20 years after diagno-
sis.3,8 Further, the vascular changes 
that occur within the eye are pre-
dictive of  vascular changes occur-
ring elsewhere in the body. 6,7 
Vision loss from diabetic 
retinopathy is best treated (and 
may be prevented) if  caught in 
time.4 Unfortunately, data from the 
U.S. and Australia show that 50% 
of  people with diabetes are not 
receiving regular eye examinations. 
9,10 These numbers are staggering 
when extrapolated to the approxi-
mately three million Canadians 
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currently living with diabetes (one-
third of  whom are unaware they 
have diabetes); a number predicted 
to increase to 3.7 million by 2020.5 
Canada’s Aboriginal people have a 
rate of  diabetes nearly five times 
that of  non-Aboriginal people, and 
are at a greater risk for vision loss 
from diabetes and its ocular com-
plications than any other ethnic 
group in Canada.5 
Eye care providers face a chal-
lenge in the management and 
coordination of  care for patients 
with diabetes. The delivery of  eye 
care must provide cost effective 
and efficient use of  resources to 
minimize preventable vision loss.
Effectiveness of current 
methods of assessment for 
diabetic retinopathy (DR) 
Assessment plays an important 
role in early detection and inter-
vention to prevent the progression 
of  diabetic retinopathy (DR). Low 
vision/blindness is substantially re-
duced among people with diabetes 
who receive recommended levels 
of  care.15 Despite the high level of  
efficacy, and both clinical and cost 
effectiveness of  DR assessment 
and treatment, problems remain 
with assessment and treatment 
compliance. Many people with 
diabetes do not access regular eye 
examinations and the barriers that 
prevent them from attending for 
assessment are numerous.
Successful distribution of  
comprehensive guidelines to 
ophthalmologists and optometrists 
in many locations have not re-
sulted in any significant impact on 
management practices for DR and 
recommendations for assessment 
and examination have been poorly 
followed.16,17,18,19 
In Canada, only 32% of  patients 
with Type 2 Diabetes meet the 
Canadian Diabetes Association 20,21 
guideline-recommended schedule of  
evaluation for diabetic retinopathy.22 
A study that  examined assessment 
patterns in five Canadian provinces 
has shown that 32% of  the popula-
tion with diabetes had not had an 
eye examination in the last 2 years 
and that another 32% had never had 
an eye examination for DR.23 
Factors affecting non-adherence 
to recommended guidelines are 
numerous. They include lack of  
awareness that diabetic retinopathy 
can lead to blindness or that severe 
retinopathy can be asymptomatic.24  
 
Preventing blindness in people with diabetes is uniquely cost-saving 
and cost-effective. There are few cases in health care that are so  
self-evident.
– JC Javitt, MD, MPH
“Blindness: We Know What It Costs! Now What?”
Cost of Blindness Symposium11 
“
”
(COO)). As per HPRAC’s recommendation, a senior representative 
from MOHLTC participates as an observer on EHCO, providing advice 
to the Council and information to the Ministry and Minister on 
Council activities.
The ultimate goal of EHCO is the delivery of accessible, safe, 
quality eye care by the provider best positioned to do so in their 
area of the Province. In doing so, wait times will decrease, quality 
of care will improve, and adverse outcomes will be minimized. The 
independent professional Colleges (CPSO and COO) will continue 
to ensure public safety through regulation of their professional 
members. The Council, through knowledge transfer and coopera-
tive sharing of best practice information, will be positioned to 
provide valuable information to all participants, including the 
Ministry, to continually improve the delivery of eye care in Ontario.
On September 23, 2011, the members of the Eye Health  
Council of Ontario unanimously passed their first inter-professional 
collaborative guideline, focusing on the care of patients with 
diabetes mellitus. We trust that these guidelines are an important 
first step in improving eye health care delivery for patients living 
with diabetes – and ultimately, for all Ontarians.
Respectfully submitted, 
Dr. Thomas-A. Noël BSc OD
Co-Chair EHCO
Chair of Registration
Provincial Council Member
College of Optometrists of Ontario
Ottawa, ON
 
Sherif El-Defrawy MD PhD FRCSC
Co-Chair EHCO
Professor and Chair
Dept of Ophthalmology, Queen’s University
Ophthalmologist in Chief
Hotel Dieu and Kingston General Hospitals
Kingston, ON
(EHCO cont'd.)
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Limited access to eye care profes-
sionals, particularly in remote areas 
25,26,27, can play a significant role. 
Fear of  laser treatment, guilt about 
poor control causing retinopathy, 
the inconvenience of  regular at-
tendance 24 and limited personal 
mobility due to poor overall health 
and self-reported apathy 28 may 
also deter patients from attending 
assessment appointments. 
Primary care provider recom-
mendation about the necessity of  a 
regular eye examination is the most 
significant predictor of  assessment 
for diabetic retinopathy and once 
such a recommendation is given, the 
assessment rate improves.29 Thus, all 
physician/allied health staff  encoun-
ters with individuals with diabetes 
should be used as an opportunity for 
education on the need for regular 
eye assessment and on risk factors 
associated with DR. 
Evidence30 indicates that 
increasing patient awareness of  
diabetic retinopathy, improving 
provider and practice performance, 
improving healthcare system infra-
structure processes to make atten-
dance more convenient for pa-
tients, using patient recall systems 
and better outreach to disadvan-
taged populations can significantly 
improve the rates of  assessment 
for diabetic retinopathy.
Any chosen assessment strat-
egy or program needs sufficient 
resource allocation and access  
to information technology to  
ensure comprehensive coverage 
and compliance with quality- 
assurance standards.31 
Goal
The goal of  these guidelines is to 
coordinate the services of  oph-
thalmologists, optometrists, family 
physicians, physician specialists, 
nurse practitioners and allied 
health staff  in the management 
of  patients with diabetes, thereby 
ensuring the most effective use of  
these professionals in the interest 
of  patient safety, quality of  care, 
accessibility and cost effectiveness.
Roles
Primary Care Providers: 
Family Physician/Physician 
Specialist/Nurse Practitioner/
Allied Health Staff
The first step in preventing ocular 
complications from diabetes is 
identifying the population at risk.  
Primary care providers, including 
family physicians, are responsible 
for identifying patients with diabe-
tes and play a key role in the care 
and treatment process. As the co-
ordinators of  patient care, primary 
care providers should promptly 
refer any newly diagnosed patient 
with Type 2 Diabetes for an assess-
ment by an optometrist (or ophthal-
mologist).  Patients over the age of  
puberty with Type 1 Diabetes need 
to be referred within five years of  
their diagnosis with diabetes. 
Pediatric patients with Type 1 
Diabetes should be referred for 
a comprehensive eye examina-
tion once the child has reached 
the age of  10, or has had diabetes 
for at least three years. Ideally, an 
ophthalmologist should perform 
this initial examination. Once the 
patient has reached the age of  13, 
in the absence of  retinopathy, the 
patient should be followed by an 
optometrist (or ophthalmologist) 
on an annual basis. 
Family physicians also need to 
ensure that their established pa-
tients with either Type 1 or Type 2  
Diabetes, but without retinopathy, 
are assessed by an optometrist (or 
ophthalmologist) annually.  Ideally, 
each referral would be accompa-
nied by fasting blood glucose and 
HbA1c levels.  
The above outlined pattern of  referral 
to an optometrist is intended to improve 
patient access to timely and consistent sur-
veillance for eye disease related to diabetes. 
While the Eye Health Council would rec-
ommend that initial referrals be directed to 
an optometrist, it is not the intent to restrict 
direct access to an ophthalmologist through 
a requirement to first see an optometrist. 
Recommendations 
n	Refer any patients over the age 
of  puberty with Type 1  
Diabetes within five years of  
their diagnosis with diabetes for 
an assessment by an optometrist 
(or ophthalmologist).  
n	Refer any patient newly diag-
nosed with Type 2 Diabetes for 
an assessment by an optom-
etrist (or ophthalmologist). The 
patient should be seen within six 
months of  the referral.
n	Refer any pediatric patient with 
Type 1 Diabetes for a compre-
hensive eye examination once 
the child has reached the age 
of  10, or has had diabetes for 
at least three years. Ideally, an 
ophthalmologist should perform 
 this initial examination. Once 
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the patient has reached the age 
of  13, in the absence of  reti-
nopathy, the patient should be 
followed by an optometrist (or 
ophthalmologist) on an annual 
basis.
n	At every visit, a patient with 
diabetes should be asked about 
their liaison with an optometrist 
or ophthalmologist to ensure  
appropriate monitoring. 
n	As mentioned later in this 
document, the optometrist and 
ophthalmologist will ensure that 
the next regular visit for their 
patient with diabetes is arranged, 
and will correspond with all ap-
propriate physicians and allied 
health staff  with ocular updates 
on the patient.
Optometrist
Optometrists will assess patients 
according to established protocols 
(see Specific Recommendation sec-
tion that follows) for ocular com-
plications of  diabetes and should 
provide a report of  the findings at 
the initial patient encounter, and 
thereafter when clinically indicated, 
to the family physician/primary 
care provider. It is helpful to pro-
vide an annual update if  the pa-
tient is being seen more frequently. 
In cases where diabetic eye disease 
is detected, optometrists should 
use generally accepted criteria 
when managing and/or referring 
the patient to an ophthalmologist 
or retinal specialist. Referral for 
subsequent care should include a 
report to the ophthalmologist and 
family physician.
Ophthalmologist
Ophthalmologists are responsible 
for assessing and (if  necessary) 
treating diabetic eye disease to 
prevent, minimize or restore vision 
loss. Patients with diabetic eye 
disease, who remain at high risk 
of  vision loss, should continue to 
be monitored by the ophthalmolo-
gist. The ophthalmologist should 
provide a report of  the findings 
at the initial patient encounter, 
and thereafter when clinically 
indicated, to the family physician/
primary care giver and optometrist.
It is helpful to provide an annual 
update if  the patient is being seen 
more frequently.
All professionals share the common 
role of  ensuring their patients are edu-
cated with respect to diabetes in general, 
and their specific clinical situation.
Initial / Ongoing Assessment
Initiation of assessment in 
people with Type 1 Diabetes
In Type 1 Diabetes, sight-threat-
ening retinopathy is very rare in 
the first five years of  diabetes or 
before puberty. 32 However, almost 
all patients with Type 1 Diabetes 
develop retinopathy over the sub-
sequent two decades33 and duration 
of  diabetes is strongly associated 
with the development and severity 
of  DR.34,35,36,37
Based on the available evidence, 
assessment for diabetic retinopathy 
in post-pubertal individuals should 
be initiated within five years of  
diagnosis.
For pre-pubertal individuals,  
assessment should be initiated at  
 
age 10 or within three years of  
diagnosis, whichever comes first.
Initiation of assessment in 
people with Type 2 Diabetes
Duration of  diabetes is the strongest 
risk factor linked to the development 
of  DR.38,39,40,41,42. DR risk is con-
tinuous with no evident glycemic or 
blood pressure threshold.75
At the time diabetes is diagnosed, 
up to 3% of  patients with diabetes 
over age 30 have CSME or high-
risk DR findings.43,44 After a 10-year 
duration of  diabetes, 7% of  persons 
with diabetes were shown to have 
retinopathy; this number increased 
to 90% after 25 years. Prolifera-
tive disease was found in 20% of  
patients after 20 years of  diabetes.45 
DR prevalence was shown to be 
lower in patients diagnosed with dia-
betes after the age of  70 years, and 
patients with DR had a significantly 
higher median duration of  diabetes 
(5.0 years) than those without DR 
(3.5 years).46
The interval between the onset 
of  symptoms and diagnosis in 
patients with Type 2 Diabetes is 
seven years. Given this and the 
foregoing information, retinopathy 
assessment for patients with Type 
2 Diabetes should be initiated at 
the time of  diagnosis.
Assessment intervals for 
people with diabetes
Since 1985, lower rates of  progres-
sion to PDR and of  severe visual 
loss from DR have been reported. 
This may reflect an increased aware-
ness of  retinopathy risk factors, 
earlier identification and care for 
patients with retinopathy as well as 
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improved glucose, blood pressure, 
and serum lipids management.47
Type 1 Diabetes
The EURODIAB Prospective 
Complications Study found that 
diabetes duration, age at onset 
before age 12 years, and metabolic 
control were significant predic-
tors of  progression, even when 
adjusted for presence of  baseline 
retinopathy.48
Specific  
Recommendations
NO rETINOPATHY
Type 1 Diabetes
Available evidence indicates 
that an annual assessment 
needs to be performed by an 
optometrist (or ophthalmolo-
gist, or telemedicine screening 
if  those doctors are not acces-
sible). 
Type 2 Diabetes
In the absence of  any DR, assess-
ment intervals of  19 to 24 months, 
as compared with intervals of  12 
to 18 months, are not associated 
with increased risk of  referable 
retinopathy,49 and biennial screen-
ing has been shown to be safe and 
effective with no person progress-
ing from having no retinopathy to 
sight-threatening retinopathy in 
under two years.50 This approach 
reduces the number of  assess-
ments by more than 25%, consid-
erably reducing health costs, strain 
on resources and relieving patients 
with diabetes from unnecessary  
examinations.51 However, screen-
ing intervals of  more than 24 
months are associated with an 
 
increased risk of  sight-threatening 
DR.49  The overriding concern, how-
ever, is that a move away from annual 
examinations will result in patients 
being lost to proper follow-up.  This is 
especially true for people with poor access 
to care. Given that the current standard 
of  care for people with Type 1 Diabetes 
is annual examinations, this will be the 
recommendation of  these guidelines for 
patients with Type 2 Diabetes. Biennial 
follow-up may be suggested for 
those patients who can be relied 
upon to recognize the need for 
recall after 24 months, or for of-
fices that are able to recall patients 
effectively at the 2-year mark.
Annual assessment of   
patients with Type 2 Diabetes 
with no retinopathy needs to be 
performed by an optometrist (or 
ophthalmologist, or telemedicine 
screening if  those doctors are 
not accessible).
PrEGNANT WOmEN WITH 
DIABETES
Before attempting to become 
pregnant, women with Type 1 
or Type 2 Diabetes should un-
dergo an ophthalmic evaluation 
by an optometrist or ophthal-
mologist. Repeat assessments 
should be performed during the 
first trimester, as needed dur-
ing pregnancy, and again within 
the first year postpartum. 76 This 
guideline does not apply to 
women who develop gestational 
diabetes, because such individ-
uals are not at increased risk for 
diabetic retinopathy.
mINImAL rETINOPATHY:  
mild NPDr
n	Several microaneurysms
n	Visual acuity of  6/6 or better 
(unless other known cause of  
decreased vision)
Annual follow-up of  patients 
with mild NPDR by an optom-
etrist (or ophthalmologist, or 
telemedicine screening if  those 
doctors are not accessible).
mODErATE rETINOPATHY:  
moderate NPDr
n	Intraretinal hemorrhages
n	Hard exudates
n	Nerve fibre layer infarcts/cotton 
wool spots (CWS)
Consider referral of  a patient 
with moderate NPDR to an 
ophthalmologist (or retinal 
specialist) if  there is any con-
cern about DME, CSME, or 
other treatable disease.  Assess-
ment of  patients with moderate 
NPDR by an eye care profes-
sional (optometrist or ophthal-
mologist) needs to occur at least 
every six months.
SEvErE rETINOPATHY:  
Severe NPDr
Severe NPDR includes all features 
of  moderate NPDR, plus any one 
of  the following:
n	Intraretinal hemorrhages (≥20 in 
each of  4 quadrants)
n	Venous beading (2 or more 
quadrants)
n	Arteriolar narrowing
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n Intraretinal microvascular ab-
normalities – IRMA (1 or more 
quadrant(s))
Very severe NPDR is defined as 
any 2 of  the criteria for severe 
NPDR.
Referral to a retinal specialist 
(or ophthalmologist) for pos-
sible treatment. Assessment by 
an ophthalmologist every 2 to 
4 months. Once stabilized, the 
patient requires follow-up by 
either an optometrist or oph-
thalmologist (or retinal special-
ist) so that assessment occurs at 
least every six months.
DIABETIC mACULAr EDEmA: 
DmE, CSmE
Clinically significant macular 
edema (CSME) is defined as74:
n	Retinal thickening at or within 
500 microns of  the fovea
n	Hard exudates at or within 500 
microns of  the fovea (if  adjacent 
retina is thickened)
n	Retinal thickening 1 disc diam-
eter or larger if  within 1 disc 
diameter of  the fovea
Referral to a retinal specialist 
(or ophthalmologist) for treat-
ment (laser, IVI). Follow-up by 
treating ophthalmologist until 
DME has stabilized or resolved. 
Once stabilized, the patient 
requires follow-up by either an 
optometrist or ophthalmologist 
(or retinal specialist) so that 
assessment occurs at least every 
six months.
PrOLIFErATIvE DIABETIC  
rETINOPATHY: PDr
n	Neovascularization of  the  
disc – NVD
n	Neovascularization elsewhere – 
NVE
n	Vitreous/pre-retinal hemorrhage
n	Neovascularization of  the iris – 
NVI (anterior segment  
neovascularization)
Referral to a retinal specialist 
(or ophthalmologist) for treat-
ment (laser, IVI, vitrectomy).   
Follow-up by treating ophthal-
mologist until regression. Once 
stabilized, the patient requires 
follow-up by either an optom-
etrist or ophthalmologist (or 
retinal specialist) so that assess-
ment occurs at least every six 
months.
Assessment Tools
Patient assessment by both oph-
thalmologist and optometrist 
includes a full examination of  all 
ocular structures and a commen-
tary on any diabetes associated 
ocular complications, rather than 
only diabetic retinopathy. Clinical 
examination to detect and assess 
DR and its severity may be per-
formed with slit lamp biomicros-
copy, ophthalmoscopy or retinal 
photography. It should include 
measurement of  visual acuity, and 
pupils should normally be dilated 
for the fundus examination. Ad-
equate sensitivity and specificity 
in performing the assessments are 
required for the examiners in all 
assessment processes. Minimum 
sensitivity required for DR has 
been set to 80% 53,54 or, in the case 
of  repeated examinations that 
would detect DR missed at earlier 
examinations, to 60%. 55 Specificity 
levels of  90-95% and technical fail-
ure rates of  5-10% are considered 
appropriate. 54
Biomicroscopy
Slit lamp biomicroscopy with a 
non-contact fundus lens after 
pupil dilation is the currently ac-
cepted standard of  practice for 
DR detection (sensitivity of  87.4% 
and specificity of  94.4%), and is 
preferred over direct ophthalmos-
copy, which has lower and more 
variable sensitivity even in the 
hands of  an experienced examiner 
(sensitivity 56-98%, specificity 62-
100%).56 Training should ensure 
examiners of  sufficient diagnostic 
accuracy and adequate sensitivity 
and specificity. 54,57 Single-field retinal 
photography or optical coherence tomog-
raphy are not replacements for a proper 
dilated retinal examination.
Retinal Photography
Stereoscopic seven-field fundus 
photography evaluated by a trained 
grader is the “gold standard” meth-
od of  detecting DR and has been 
used in most of  the large clinical tri-
als in this area. However, it is costly 
and time consuming and is used 
rarely in routine practice.  Single-field 
retinal photography can be useful 
for documentation and follow-up 
purposes as a part of  a comprehen-
sive examination by an optometrist 
or ophthalmologist.
Telemedicine
Digital retinal photography is in-
creasingly being used in screening 
for DR. It is not a substitute for a 
comprehensive eye examination, 
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but in circumstances where there is 
no optometrist or ophthalmologist 
available, there is level I evidence 
that it can serve as a screening tool 
for diabetic retinopathy.  Patients 
identified as having retinopathy 
through this method should be 
referred to an optometrist or oph-
thalmologist for further evaluation 
and management.58,59,60,61,62,63
Fundus imaging has the addi-
tional advantage of  being perceived 
by patients as a valuable educa-
tional resource.24 It can be per-
formed with dilated pupils or with 
non-mydriatic cameras through 
non-dilated pupils.64 The chosen 
technology, along with the number 
of  camera fields taken, will influ-
ence sensitivity of  screening. 65
Fluorescein Angiography (FA)
Fluorescein angiography has no 
role in screening for DR, but is 
essential in late-stage disease to de-
tect and delineate retinal ischemia. 
It is an invasive examination with 
an inherent albeit small risk of  
significant side effects, some mild 
and transient, some severe (such as 
anaphylaxis or cardiac arrest). 
Optical Coherence  
Tomography (OCT)
Optical coherence tomography is a 
non-contact, non-invasive tech-
nique that produces cross-sectional 
images of  the retina and optic disc 
similar to histological sections. It 
has an axial resolution of  5 μm 
with newer instruments and pro-
vides qualitative and quantitative 
data that correlate well with fundus 
stereophotography or biomicros-
copy to diagnose diabetic macular 
edema. It has good reproducibility 
and provides accurate measure-
ments of  retinal thickness.67,68  
OCT appears useful to detect 
macular thickening in the early 
stages of  diabetic retinopathy 
in patients with retinopathy and 
no clinical evidence of  macular 
edema, enabling closer follow-up 
for early DME.69,70 However, OCT 
does not help in predicting which 
eyes with subclinical DME will 
progress to clinically significant 
DME.71
OCT is an effective qualita-
tive and quantitative method for 
detecting early macular thicken-
ing and following progression or 
regression of  macular edema over 
the course of  treatment, and has 
been incorporated as a routine 
measure in numerous ongoing 
studies of  new treatments for DR. 
Current data suggest that there 
is little reason to routinely obtain 
OCT in eyes with diabetes and no 
retinopathy or mild to moderate 
diabetic retinopathy when clinical 
examination fails to show macular 
edema.72 However, OCT should 
be strongly considered when any 
change in macular architecture, or 
any unexplained change in best-
corrected acuity, is encountered.
Conclusion
The coordination of  health care 
resources is essential in the care 
and treatment of  patients at risk 
for ocular complications from 
diabetes. Timely optometric assess-
ment of  newly diagnosed diabetic 
patients will identify patients at 
risk for diabetic eye disease. Early 
intervention and treatment of  eye 
disease through appropriate and 
timely referral for ophthalmologic 
care will assist in the preservation 
of  quality vision for patients with 
diabetes. Inter-professional guide-
lines and generally accepted man-
agement and referral criteria will 
ensure appropriate coordination of  
care and the most effective use of  
health professional resources.
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No Apparent Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy 
(NPDR)
l Mild to moderate NPDR – micro-
aneurysms, intra-retinal hemorrhages, 
hard exudates, foveal avascular zone 
abnormalities
l Moderate to severe NPDR – cotton 
wool spots, venous beading, intra-retinal 
microvascular abnormalities (IRMA)
l Severe NPDR (4-2-1 rule) – any one of: 
severe (>20) intra-retinal hemorrhages in 
each of  four quadrants; definite venous 
beading in two or more quadrants; 
prominent IRMA in one or more 
quadrant(s)
l Very severe NPDR – any two of  the 
above criteria
Proliferative Diabetic Retinopathy (PDR) 
– one or more of:
l Neovascularization of  the disc – NVD 
(particularly greater than 1 disc diameter 
in size)
l Neovascularization elsewhere – NVE
l Vitreous/pre-retinal hemorrhage
l Neovascularization of  the iris – NVI 
(anterior segment neovascularization)
Clinically Significant (Diabetic) Macular 
Edema (CSME)
l Any retinal thickening within 500 
microns of  the center of  the macula 
(fovea), or;
l Retinal thickening at least one disc area 
in size, any part of  which is within one 
disc diameter of  the center of  the macula 
(fovea), or;
l Hard exudates within 500 microns of  
the center of  the macula (fovea) with 
adjacent retinal thickening.
 It is important to note that hard exudates 
are a sign of  current or previous macular 
edema. CSME may be focal (leakage 
from micro-aneurysms or IRMA) or 
diffuse (leakage from the underlying 
capillary bed). CSME is the most 
common cause of  decreased vision and 
blindness among patients with diabetes, 
and may occur concurrent with any stage 
of  diabetic retinopathy.
Appendix: Diabetic Retinopathy (DR) Disease Severity Scale
